Shennon Biotechnologies

About Shennon Biotechnologies

Shennon Biotechnologies is focused on accelerating drug development by profiling millions of cell-cell interactions at the single-cell level using their proprietary ultrafast screening platform and AI models. Their mission is to identify novel targets and develop more effective and safer drugs for cancer and autoimmune diseases.

Products & Services

TCELERATOR™ Platform:A proprietary ultrafast screening platform that functionally and dynamically profiles millions of single-cell interactions to find rare populations and screen for immune-modulating agents by specific function.

Proprietary AI Models:AI models combined with the TCELERATOR™ platform to enhance drug development, leading to faster, safer, and more effective drugs.

Specialties

Ultrafast Single-Cell Functional Screening AI in Drug Development Immunotherapy Cancer Treatment Autoimmune Disease Treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 13000000 MR: - FA: $13M FAN: 13000000	D: 2023-03-13 FD: 2023-03-13	4 investors

Seed Latest

2023-03-13

$13.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

L

Li Sun

CEO & Founder

LinkedIn (Pro only)

K

Kaitao Li

Associate Director

LinkedIn (Pro only)

I

Ian Chen

Staff Engineer

LinkedIn (Pro only)

M

Michael Malone

Senior Scientist

K

Kelsy Cotto

Senior Computational Biologist

T

Tek Hyung Lee

Senior Scientist

View 21 more team members with Pro

Unlock Full Team Directory

Recent News